API XML

Aop: 217

AOP Title

?


Gastric ulcer formation

Short name:

?

Gastric ulcer formation

Graphical Representation

?

Click to download graphical representation template

Authors

?


Point of Contact

?


Lyle Burgoon   (email point of contact)

Contributors

?


  • Hsin-Yen Wu
  • Lyle Burgoon
  • Edward Perkins

Status

?

Author status OECD status OECD project SAAOP status
Under development: Not open for comment. Do not cite Under Development


This AOP was last modified on July 24, 2017 15:37

?

Revision dates for related pages

Page Revision Date/Time
Inhibit, gastric ulcer formation April 17, 2017 10:47
Inhibition, PTGS-1 (Prostaglandin-endoperoxide synthase 1) April 17, 2017 10:19
Activation, PTGS-1 (Prostaglandin-endoperoxide synthase 1) April 17, 2017 10:20
Activation, PTGS-2 (Prostaglandin-endoperoxide synthase 2) April 17, 2017 10:21
Inhibition, PTGS-2 (Prostaglandin-endoperoxide synthase 2) April 17, 2017 10:21
Increase, bicarbonate April 17, 2017 10:23
Increase, mucous April 17, 2017 10:23
Increase, mucosal blood flow April 17, 2017 10:24
Increase, platelet aggregation April 17, 2017 10:25
Increase, angiogenesis April 17, 2017 10:26
Decrease, leukocyte adherence April 17, 2017 10:27
Increase, leukocyte adherence April 17, 2017 10:28
Activate, leukocyte April 17, 2017 10:29
Activate, mucosal defense April 17, 2017 10:30
Increase, surfactant April 17, 2017 10:31
Decrease, surfactant April 17, 2017 10:32
Activate, phospholipase April 17, 2017 10:33
Increase, ammonium (NH4+) April 17, 2017 10:34
Activated, gastric ulcer formation June 02, 2017 10:26
Increase, angiogenesis leads to Inhibit, gastric ulcer formation April 17, 2017 10:49
Increase, platelet aggregation leads to Inhibit, gastric ulcer formation April 17, 2017 10:49
Activate, mucosal defense leads to Inhibit, gastric ulcer formation April 17, 2017 10:49
Activate, leukocyte leads to Activated, gastric ulcer formation April 17, 2017 10:50
Increase, leukocyte adherence leads to Activate, leukocyte April 17, 2017 10:50
Activation, PTGS-2 leads to Decrease, leukocyte adherence April 17, 2017 10:51
Activation, PTGS-2 leads to Increase, angiogenesis April 17, 2017 10:51
Activation, PTGS-1 leads to Increase, platelet aggregation April 17, 2017 10:52
Activation, PTGS-1 leads to Increase, mucosal blood flow April 17, 2017 10:52
Activation, PTGS-1 leads to Increase, mucous April 17, 2017 10:53
Activation, PTGS-1 leads to Increase, bicarbonate April 17, 2017 10:53
Increase, bicarbonate leads to Activate, mucosal defense April 17, 2017 10:54
Increase, mucous leads to Activate, mucosal defense April 17, 2017 10:54
Increase, mucosal blood flow leads to Activate, mucosal defense April 17, 2017 10:54
Increase, ammonium (NH4+) leads to Decrease, surfactant April 17, 2017 10:55
Activate, phospholipase leads to Decrease, surfactant April 17, 2017 10:55
Increase, surfactant leads to Activate, mucosal defense April 17, 2017 10:56
NonSteroidal Anti-Inflammatory Drugs (NSAID) April 17, 2017 10:12
Helicobacter pylori April 17, 2017 10:13

Abstract

?



Background (optional)

?



Summary of the AOP

?


Events: Molecular Initiating Events (MIE)

?

Key Events (KE)

?

Adverse Outcomes (AO)

?

Sequence Type Event ID Title Short name
1 KE 1368 Inhibition, PTGS-1 (Prostaglandin-endoperoxide synthase 1) Inhibition, PTGS-1
2 KE 1369 Activation, PTGS-1 (Prostaglandin-endoperoxide synthase 1) Activation, PTGS-1
3 KE 1370 Activation, PTGS-2 (Prostaglandin-endoperoxide synthase 2) Activation, PTGS-2
4 KE 1371 Inhibition, PTGS-2 (Prostaglandin-endoperoxide synthase 2) Inhibition, PTGS-2 (Prostaglandin-endoperoxide synthase 2)
5 KE 1372 Increase, bicarbonate Increase, bicarbonate
6 KE 1373 Increase, mucous Increase, mucous
7 KE 1374 Increase, mucosal blood flow Increase, mucosal blood flow
8 KE 1375 Increase, platelet aggregation Increase, platelet aggregation
9 KE 1376 Increase, angiogenesis Increase, angiogenesis
10 KE 1377 Decrease, leukocyte adherence Decrease, leukocyte adherence
11 KE 1378 Increase, leukocyte adherence Increase, leukocyte adherence
12 KE 1379 Activate, leukocyte Activate, leukocyte
13 KE 1380 Activate, mucosal defense Activate, mucosal defense
14 KE 1381 Increase, surfactant Increase, surfactant
15 KE 1382 Decrease, surfactant Decrease, surfactant
16 KE 1383 Activate, phospholipase Activate, phospholipase
17 KE 1384 Increase, ammonium (NH4+) Increase, ammonium (NH4+)
18 AO 1367 Inhibit, gastric ulcer formation Inhibit, gastric ulcer formation
19 AO 1385 Activated, gastric ulcer formation Activated, gastric ulcer formation

Relationships Between Two Key Events
(Including MIEs and AOs)

?

Title Adjacency Evidence Quantitative Understanding
Increase, angiogenesis leads to Inhibit, gastric ulcer formation adjacent
Increase, platelet aggregation leads to Inhibit, gastric ulcer formation adjacent
Activate, mucosal defense leads to Inhibit, gastric ulcer formation adjacent
Activate, leukocyte leads to Activated, gastric ulcer formation adjacent
Increase, leukocyte adherence leads to Activate, leukocyte adjacent
Activation, PTGS-2 leads to Decrease, leukocyte adherence adjacent
Activation, PTGS-2 leads to Increase, angiogenesis adjacent
Activation, PTGS-1 leads to Increase, platelet aggregation adjacent
Activation, PTGS-1 leads to Increase, mucosal blood flow adjacent
Activation, PTGS-1 leads to Increase, mucous adjacent
Activation, PTGS-1 leads to Increase, bicarbonate adjacent
Increase, bicarbonate leads to Activate, mucosal defense adjacent
Increase, mucous leads to Activate, mucosal defense adjacent
Increase, mucosal blood flow leads to Activate, mucosal defense adjacent
Increase, ammonium (NH4+) leads to Decrease, surfactant adjacent
Activate, phospholipase leads to Decrease, surfactant adjacent
Increase, surfactant leads to Activate, mucosal defense adjacent

Network View

?

 

Stressors

?

Life Stage Applicability

?

Taxonomic Applicability

?

Sex Applicability

?

Overall Assessment of the AOP

?



Domain of Applicability

?


Essentiality of the Key Events

?


Evidence Assessment

?


Quantitative Understanding

?


Considerations for Potential Applications of the AOP (optional)

?



References

?